Editorial
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Stem Cells. Apr 26, 2011; 3(4): 25-33
Published online Apr 26, 2011. doi: 10.4252/wjsc.v3.i4.25
Adipose-derived stromal cells: Their identity and uses in clinical trials, an update
Louis Casteilla, Valérie Planat-Benard, Patrick Laharrague, Béatrice Cousin
Louis Casteilla, Valérie Planat-Benard, Patrick Laharrague, Béatrice Cousin, Université de Toulouse, UPS, UMR 5241 Métabolisme, Plasticité et Mitochondrie, BP 84225, F-31 432 Toulouse Cedex 4, France
Louis Casteilla, Valérie Planat-Benard, Patrick Laharrague, Béatrice Cousin, CNRS, UMR 5241 Métabolisme, Plasticité et Mitochondrie, BP 84 225, F-31 432 Toulouse, France
Patrick Laharrague, Laboratoire d’Hématologie, CHU Toulouse, France
Author contributions: All authors wrote the paper.
Supported by FP7 program (CADSCADE), Etablissement Français du Sang Pyrénées-Mediterranée, Fondation pour la Recherche Médicale (Programme “Vieillissement Cardiovadsculaire Normal et Pathologique”, project DCV20070409252) and CTP “transpyreneen stem cells group”
Correspondence to: Louis Casteilla, PhD, CNRS, University Paul Sabatier, UMR 5241 BP 84225, F-31 432 Toulouse Cedex 4, France. louis.casteilla@inserm.fr
Telephone: +33-5-62170904 Fax: +33-5-62170905
Received: March 31, 2010
Revised: December 14, 2010
Accepted: December 21, 2010
Published online: April 26, 2011
Abstract

In adults, adipose tissue is abundant and can be easily sampled using liposuction. Largely involved in obesity and associated metabolic disorders, it is now described as a reservoir of immature stromal cells. These cells, called adipose-derived stromal cells (ADSCs) must be distinguished from the crude stromal vascular fraction (SVF) obtained after digestion of adipose tissue. ADSCs share many features with mesenchymal stem cells derived from bone marrow, including paracrine activity, but they also display some specific features, including a greater angiogenic potential. Their angiogenic properties as well as their paracrine activity suggest a putative tumor-promoting role for ADSCs although contradictory data have been published on this issue. Both SVF cells and ADSCs are currently being investigated in clinical trials in several fields (chronic inflammation, ischemic diseases, etc.). Apart from a phase III trial on the treatment of fistula, most of these are in phase I and use autologous cells. In the near future, the end results of these trials should provide a great deal of data on the safety of ADSC use.

Keywords: Mesenchymal stem cells, Stroma cells, Cell therapy, White adipose tissue